Given that the frequency of taking biguanides or insulin therapy was slightly higher in the non‐sarcopenia group, further studies with detailed assessment of insulin resistance, such as the use of an oral glucose tolerance test, might help clarify this issue. The gene discussed is INS; the disease is sarcopenia.